BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 28349165)

  • 1. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
    Nagato T; Ohkuri T; Ohara K; Hirata Y; Kishibe K; Komabayashi Y; Ueda S; Takahara M; Kumai T; Ishibashi K; Kosaka A; Aoki N; Oikawa K; Uno Y; Akiyama N; Sado M; Takei H; Celis E; Harabuchi Y; Kobayashi H
    Cancer Immunol Immunother; 2017 Jul; 66(7):877-890. PubMed ID: 28349165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.
    Jo JC; Kim M; Choi Y; Kim HJ; Kim JE; Chae SW; Kim H; Cha HJ
    Ann Hematol; 2017 Jan; 96(1):25-31. PubMed ID: 27696202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
    Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
    Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
    Feng Y; Jing C; Yu X; Cao X; Xu C
    Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27.
    Yoshino K; Kishibe K; Nagato T; Ueda S; Komabayashi Y; Takahara M; Harabuchi Y
    Br J Haematol; 2013 Feb; 160(3):331-42. PubMed ID: 23206232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
    Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
    J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
    Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
    Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
    Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
    Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.
    Kumai T; Nagato T; Kobayashi H; Komabayashi Y; Ueda S; Kishibe K; Ohkuri T; Takahara M; Celis E; Harabuchi Y
    Cancer Immunol Immunother; 2015 Jun; 64(6):697-705. PubMed ID: 25754123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
    Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
    Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
    Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
    Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type.
    Kim SJ; Kim BS; Choi CW; Choi J; Kim I; Lee YH; Kim JS
    Ann Oncol; 2007 Aug; 18(8):1382-7. PubMed ID: 17693651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma.
    Sakata K; Someya M; Omatsu M; Asanuma H; Hasegawa T; Ichimiya S; Hareyama M; Himi T
    BMC Cancer; 2007 Dec; 7():229. PubMed ID: 18093334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma.
    Shiraishi T; Toyozumi T; Sakata H; Murakami K; Kano M; Matsumoto Y; Yokoyama M; Okada K; Kamata T; Ryuzaki T; Kinoshita K; Hirasawa S; Matsubara H
    Oncology; 2022; 100(1):39-47. PubMed ID: 34991094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
    Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
    Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
    Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.